Smoking and the Global Burden of Rheumatoid Arthritis

Save

RA leads to ILD: but ILD does not lead to RA

Save

Rheumatoid arthritis is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.

Juvenile Idiopathic Arthritis - NEJM Review

Save

Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).

2025 BSR Recommendations for ANCA-associated Vasculitis

Save

The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).

Rheums Speak - RA Treatment Survey

Save

RheumNow's August 2025 “Live Vote” surveys examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. The first survey on RA Treatment (7/28/2025) sheds light on evolving prescribing habits, use of biologics, and key frustrations in RA care.

Aging Quiets Lupus

Save

UCSF researchers have found that epigentic changes in interferon genes over time may lead to lupus being less active as they age. Lupus is a “classic” autoimmune disease. It causes the immune system’s first-line viral defenses — known as interferons — to attack the body. Nearly every organ is at risk, leading to conditions like kidney and heart disease. But unlike many other autoimmune or chronic illnesses, lupus can improve as patients reach their 60s and 70s.

A New RA Approval (8.1.2025)

Save

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

FDA Approves Vagal Nerve Stimulator for RA

Save

SetPoint Medical announced that the FDA has approved the company’s SetPoint System, a first-in-class neuroimmune modulation innovation for treatment of moderate-to-severe rheumatoid arthritis (RA) for those who are not adequately managed by—or cannot tolerate—existing advanced RA therapies, such as biological and targeted synthetic DMARDs.

Options for Refractory axSpA or PsA

Save

Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such cases, a Danish registry study indicated.

Rituximab is not Superior in EGPA

Save

A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination with cyclophosphamide.

Rheumatology Salaries Remain Low

Save

The annual Medscape Physician Compensation report was published and shows only modest salary gains for most specialists.

Top 20 Best Rheumatology Hospitals - 2025

Save

U.S. News & World Report has published its Best Hospitals for 2025, listing the best among many specialties, including rheumatology.  Each year, U.S. News ranks hospitals in 15 specialties and for the 8th year in a row, Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report.